ArticleAdvanced healthcare materials2026
Dual Targeted Far-Red Emissive Small Molecules for Mitochondrial Imaging and Multifunctional Modulation in Alzheimer's Disease.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Alzheimer's disease (AD), the leading cause of age-related dementia, is a multifactorial neurodegenerative disorder associated with amyloid-β (Aβ) aggregation, metal ion dyshomeostasis, oxidative stress, and mitochondrial dysfunction. The pathological interplay among these processes necessitates multifunctional small molecules capable of both diagnosis and therapeutic intervention. Herein, we report two triphenylamine (TPA)-based aggregation-induced emission (AIE) luminogens, TPA-RPA (triphenylamine-rhodaninepropanoic acid) and TPA-ER (triphenylamine-ethylrhodanine), designed as mitochondria-active anti-amyloid theranostic agents. Among them, TPA-RPA emerged as the lead candidate, exhibiting far-red emission and a pronounced ∼5-fold fluorescence turn-on response upon selective binding to Aβ40 fibrils, enabling sensitive detection of pathogenic aggregates. TPA-RPA effectively inhibited Aβ40 fibrillogenesis, disaggregated preformed fibrils, binds with selective metal ions Fe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.